Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,

Published byClyde Chapman Modified over 5 years ago

Similar presentations

Presentation on theme: "Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,"— Presentation transcript:

1 Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim, MD, PhD, Donghyun Kim, MS, Bhumsuk Keam, MD, Tae Min Kim, MD, PhD, Se-Hoon Lee, MD, PhD, Dae Seog Heo, MD, PhD, Yung-Jue Bang, MD, PhD, Doo Hyun Chung, MD, PhD  Journal of Thoracic Oncology  Volume 8, Issue 11, Pages (November 2013) DOI: /JTO.0b013e3182a4dd6e Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 ROS1 FISH patterns of lung adenocarcinomas. A, Tumor cell nuclei with wild-type ROS1 showed nonsplit of two yellow or closely apposed green and red signals. B, ROS1-rearranged cases with a split pattern showed a pattern with more than a one-signal-size split between green and red signals. C, ROS1-rearranged cases with isolated 3′ ends showed one or more isolated red signals and intact fusion signals. FISH, fluorescence in situ hybridization. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e3182a4dd6e) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Pathologic features of a case with ROS1 rearrangements. A, Solid pattern, (B) micropapillary pattern, (C) signet-ring cell component, and (D) mucinous cribriform pattern. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e3182a4dd6e) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Seoul National University Hospital molecular enrichment strategies for ROS1 rearrangements. Histologic examination of NSCLC has to be preceded with biopsy, resection, or cytologic specimens before molecular tests for confirming adenocarcinoma. After screening for mutations of EGFR and KRAS and the fusion of ALK, the triple negative adenocarcinomas–selected ROS1 FISH test seemed to be effective for finding ROS1 rearrangements. NSCLC, non–small-cell lung cancer; FISH, fluorescence in situ hybridization; TKI, tyrosine kinase inhibitor. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e3182a4dd6e) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm  Heounjeong Go, MD, PhD, Dong-Wan Kim,"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.
Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.
Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.
Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M
Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer  Patrizia Viola, MD, Manisha Maurya,

A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer  Patrizia Viola, MD, Manisha Maurya,
Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 

Tetsuya Mitsudomi, MD, Hirohito Tada, MD  Journal of Thoracic Oncology 
How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples  Takahiro Nakajima,

How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples  Takahiro Nakajima,
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases  Jennifer M. Boland, MD, Jin.

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases  Jennifer M. Boland, MD, Jin.

Similar presentations

Ads by Google